Advances in antidepressants for treating post-stroke depression

Expert Opinion on Pharmacotherapy

Volumn 18, Issue 10, 2017, Pages 1011-1017

  Paolucci, Stefano ^a  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

antidepressants; Depression; functional outcome; rehabilitation; stroke

Indexed keywords

AGOMELATINE; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; MILNACIPRAN; MIRTAZAPINE; NEFIRACETAM; PIOGLITAZONE; REBOXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VORTIOXETINE; PIPERAZINE DERIVATIVE; SULFIDE;

DRUG EFFICACY; DRUG SAFETY; FUNCTIONAL STATUS; HUMAN; POST-STROKE DEPRESSION; REVIEW; RISK FACTOR; STROKE REHABILITATION; SYMPTOM; TREATMENT DURATION; COGNITION; COMPLICATION; DEPRESSION; DEPRESSIVE DISORDER; DRUG EFFECTS; PSYCHOLOGY; QUALITY OF LIFE; STROKE;

ANTIDEPRESSIVE AGENTS; COGNITION; DEPRESSION; DEPRESSIVE DISORDER; HUMANS; PIPERAZINES; QUALITY OF LIFE; SEROTONIN UPTAKE INHIBITORS; STROKE; SULFIDES;

EID: 85021685673     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1080/14656566.2017.1334765     Document Type: Review

References (99)

1. Jorgensen TS, Wium-Andersen IK, Wium-Andersen MK, et al. Incidence of depression after stroke, and associated risk factors and mortality outcomes, in a large cohort of Danish patients. JAMA Psychiatry. 2016;73:1032–1040.
2. Ayerbe L, Ayis S, Wolfe CD, et al. Natural history, predictors and outcomes of depression after stroke:systematic review and meta-analysis. Br J Psychiatry. 2013;202:14–21.•• Recent important review on natural history of PSD.
3. Hackett ML, Yapa C, Parag V, et al. Frequency of depression after stroke:a systematic review of observational studies. Stroke. 2005;36:1330–1340.
4. Bartoli F, Lillia N, Lax A, et al. Depression after stroke and risk of mortality:a systematic review and meta-analysis. Stroke Res Treat. 2013;2013:862978.•• Important review on risk of mortality in patients with PSD.
5. Ayerbe L, Ayis S, Crichton SL, et al. Explanatory factors for the increased mortality of stroke patients with depression. Neurology. 2014;83:2007–2012.
6. Eriksson M, Glader EL, Norrving B, et al. Poststroke suicide attempts and completed suicides:a socioeconomic and nationwide perspective. Neurology. 2015;84:1732–1738.
7. Paolucci S, Ngeh J., Suicide in stroke survivors:frequency and risk factors. Neurology. 2015;84:1724–1725.
8. Pohjasvaara T, Vataja R, Leppavuori A, et al. Depression is an independent predictor of poor long-term functional outcome post-stroke. Eur J Neurol. 2001;8:315–319.
9. Ramasubbu R, Robinson RG, Flint AJ, et al. Functional impairment associated with acute poststroke depression:the Stroke Data Bank Study. J Neuropsychiatry Clin Neurosci. 1998;10:26–33.
10. Kauhanen M, Korpelainen JT, Hiltunen P, et al. Poststroke depression correlates with cognitive impairment and neurological deficits. Stroke. 1999;30:1875–1880.
11. Jorgensen L, Engstad T, Jacobsen BK., Higher incidence of falls in long-term stroke survivors than in population controls:depressive symptoms predict falls after stroke. Stroke. 2002;33:542–547.
12. Paolucci S, Di Vita A, Massicci R, et al. Impact of participation on rehabilitation results:a multivariate study. Eur J Phys Rehabil Med. 2012;48:455–466.
13. Gillen R, Tennen H, McKee TE, et al. Depressive symptoms and history of depression predict rehabilitation efficiency in stroke patients. Arch Phys Med Rehabil. 2001;82:1645–1649.
14. Paolucci S, Antonucci G, Grasso MG, et al. Post-stroke depression, antidepressant treatment and rehabilitation results. A case-control study. Cerebrovasc Dis. 2001;12:264–271.
15. Jonsson AC, Lindgren I, Hallstrom B, et al. Determinants of quality of life in stroke survivors and their informal caregivers. Stroke. 2005;36:803–808.
16. Visser MM, Aben L, Heijenbrok-Kal MH, et al. The relative effect of coping strategy and depression on health-related quality of life in patients in the chronic phase after stroke. J Rehabil Med. 2014;46:514–519.
17. Chemerinski E, Robinson RG, Kosier JT. Improved recovery in activities of daily living associated with remission of poststroke depression. Stroke. 2001;32:113–117.
18. Dong JY, Zhang YH, Tong J, et al. Depression and risk of stroke:a meta-analysis of prospective studies. Stroke. 2012;43:32–37.
19. Gonda X, Pompili M, Serafini G, et al. The role of cognitive dysfunction in the symptoms and remission from depression. Ann Gen Psychiatry. 2015;14:27.
20. Lees R, Fearon P, Harrison JK, et al. Cognitive and mood assessment in stroke research:focused review of contemporary studies. Stroke. 2012;43:1678–1680.
21. Hackett ML, Anderson CS, House A, et al. Interventions for treating depression after stroke. Cochrane Database Syst Rev. 2008;4:CD003437.•• Important review on treatment of PSD.
22. Winstein CJ, Stein J, Arena R, et al. Guidelines for adult stroke rehabilitation and recovery:a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2016;47:e98–e169.•• New American Guidelines on stroke rehabilitation and related complications, including PSD.
23. Shen X, Liu M, Cheng Y, et al. Repetitive transcranial magnetic stimulation for the treatment of post-stroke depression:a systematic review and meta-analysis of randomized controlled clinical trials. J Affect Disord. 2017;211:65–74.
24. Eng JJ, Reime B. Exercise for depressive symptoms in stroke patients:a systematic review and meta-analysis. Clin Rehabil. 2014;28:731–739.
25. El Husseini N, Goldstein LB, Peterson ED, et al. Depression and antidepressant use after stroke and transient ischemic attack. Stroke. 2012;43:1609–1616.
26. Ruddell M, Spencer A, Hill K, et al. Fluoxetine vs placebo for depressive symptoms after stroke:failed randomised controlled trial. Int J Geriatr Psychiatry. 2007;22:963–965.
27. • Recent update on pathogenesis of depression.
28. Malberg JE. Increasing hippocampal neurogenesis:a novel mechanism for antidepressant drugs. Curr Pharm Des. 2005;11:145–155.
29. Berton O, Nestler EJ. New approaches to antidepressant drug discovery:beyond monoamines. Nat Rev Neurosci. 2006;7:137–151.
30. Encinas JM, Vaahtokari A, Enikolopov G. Fluoxetine targets early progenitor cells in the adult brain. Proc Natl Acad Sci U S A. 2006;103:8233–8238.
31. Wiart L, Petit H, Joseph PA, et al. Fluoxetine in early poststroke depression:a double-blind placebo-controlled study. Stroke. 2000;31:1829–1832.
32. Cramer SC. Repairing the human brain after stroke. II. Restorative therapies. Ann Neurol. 2008;63:549–560.
33. Hackett ML, Anderson CS, House AO. Interventions for treating depression after stroke. Cochrane Database Syst Rev. 2004;3:CD003437.
34. Chen Y, Guo JJ. Meta-analysis of antidepressant treatment for patients with poststroke depression. Stroke. 2006;37:1365–1366.
35. Rayner L, Price A, Evans A, et al. Antidepressants for depression in physically ill people. Cochrane Database Syst Rev. 2010;3:CD007503.
36. Xu XM, Zou DZ, Shen LY, et al. Efficacy and feasibility of antidepressant treatment in patients with post-stroke depression. Medicine (Baltimore). 2016;95:e5349.•• Recent important meta-analysis on treatment of PSD.
37. Towfighi A, Ovbiagele B, El HN, et al. Poststroke depression:a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2017;48:e30–e43.
38. Boustani M, Campbell N, Munger S, et al. Impact of anticholinergics on the aging brain:a review and practical application. Aging Health. 2008;4:311–320.
39. Stahl SM. Stahl’s essential psychopharmacology:neuroscientific basis. 4th ed. Cambridge University Press; Cambridge, UK, 2013.
40. Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions:an update. Curr Drug Metab. 2002;3:13–37.
41. Choi-Kwon S, Han SW, Kwon SU, et al. Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness:a double-blind, placebo-controlled study. Stroke. 2006;37:156–161.
42. Fruehwald S, Gatterbauer E, Rehak P, et al. Early fluoxetine treatment of post-stroke depression A three-month double-blind placebo-controlled study with an open-label long-term follow up. J Neurol. 2003;250:347–351.
43. Robinson RG, Schultz SK, Castillo C, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke:a placebo-controlled, double-blind study. Am J Psychiatry. 2000;157:351–359.
44. Murray V, Von Arbin M, Bartfai A, et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. J Clin Psychiatry. 2005;66:708–716.
45. Spalletta G, Caltagirone C. Sertraline treatment of post-stroke major depression:an open study in patients with moderate to severe symptoms. Funct Neurol. 2003;18:227–232.
46. Karaiskos D, Tzavellas E, Spengos K, et al. Duloxetine versus citalopram and sertraline in the treatment of poststroke depression, anxiety, and fatigue. J Neuropsychiatry Clin Neurosci. 2012;24:349–353.
47. Tan S, Huang X, Ding L, et al. Efficacy and safety of citalopram in treating post-stroke depression:a meta-analysis. Eur Neurol. 2015;74:188–201.
48. Gao J, Lin M, Zhao J, et al. Different interventions for post-ischaemic stroke depression in different time periods:A single-blind randomized controlled trial with stratification by time after stroke. Clin Rehabil. 2017;31:78–81.
49. Jorge RE, Acion L, Moser D, et al. Escitalopram and enhancement of cognitive recovery following stroke. Arch Gen Psychiatry. 2010;67:187–196.
50. Robinson RG, Jorge RE, Moser DJ, et al. Escitalopram and problem-solving therapy for prevention of poststroke depression:a randomized controlled trial. Jama. 2008;299:2391–2400.
51. Salter KL, Foley NC, Zhu L, et al. Prevention of poststroke depression:does prophylactic pharmacotherapy work? J Stroke Cerebrovasc Dis. 2013;22:1243–1251.
52. Kim JS, Lee EJ, Chang DI, et al. Efficacy of early administration of escitalopram on depressive and emotional symptoms and neurological dysfunction after stroke:a multicentre, double-blind, randomised, placebo-controlled study. Lancet Psychiatry. 2017;4:33–41.
53. Skop BP, Brown, Tm. Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Psychosomatics. 1996;37:12–16.
54. Maurer-Spurej E, Pittendreigh C, Solomons K. The influence of selective serotonin reuptake inhibitors on human platelet serotonin. Thromb Haemost. 2004;91:119–128.
55. Hackam DG, Mrkobrada M. Selective serotonin reuptake inhibitors and brain hemorrhage:a meta-analysis. Neurology. 2012;79:1862–1865.
56. Howland RH. Antidepressant drugs and the risk of intracranial bleeding:parsing an observational study. J Psychosoc Nurs Ment Health Serv. 2016;54:21–24.
57. Lam RW. Antidepressants and QTc prolongation. J Psychiatry Neurosci. 2013;38:E5–E6.
58. Mortensen JK, Johnsen SP, Larsson H, et al. Early antidepressant treatment and all-cause 30-day mortality in patients with ischemic stroke. Cerebrovasc Dis. 2015;40:81–90.
59. Mortensen JK, Larsson H, Johnsen SP, et al. Post stroke use of selective serotonin reuptake inhibitors and clinical outcome among patients with ischemic stroke:a nationwide propensity score-matched follow-up study. Stroke. 2013;44:420–426.
60. Ried LD, Jia H, Feng H, et al. Selective serotonin reuptake inhibitor treatment and depression are associated with poststroke mortality. Ann Pharmacother. 2011;45:888–897.
61. Bartoli F, Paolucci S. Association of depression and SSRIs with mortality after stroke. Neurology. 2014;83:1998–1999.
62. Lee YC, Lin CH, Lin MS, et al. Comparison of the effects of serotonin-norepinephrine reuptake inhibitors versus selective serotonin reuptake inhibitors on cerebrovascular events. J Clin Psychiatry. 2016;77:e1–e7.
63. Aiyer R, Barkin RL, Bhatia A. Treatment of neuropathic pain with venlafaxine:a systematic review. Pain Med. 2016.
64. Dahmen N, Marx J, Hopf HC, et al. Therapy of early poststroke depression with venlafaxine:safety, tolerability, and efficacy as determined in an open, uncontrolled clinical trial. Stroke. 1999;30:691–692.
65. Cravello L, Caltagirone C, Spalletta G. The SNRI venlafaxine improves emotional unawareness in patients with post-stroke depression. Hum Psychopharmacol. 2009;24:331–336.
66. Kimura M, Kanetani K, Imai R, et al. Therapeutic effects of milnacipran, a serotonin and noradrenaline reuptake inhibitor, on post-stroke depression. Int Clin Psychopharmacol. 2002;17:121–125.
67. Yamakawa Y, Satoh S, Sawa S, et al. Efficacy of milnacipran on poststroke depression on inpatient rehabilitation. Psychiatry Clin Neurosci. 2005;59:705–710.
68. Tsai CS, Wu CL, Chou SY, et al. Prevention of poststroke depression with milnacipran in patients with acute ischemic stroke:a double-blind randomized placebo-controlled trial. Int Clin Psychopharmacol. 2011;26:263–267.
69. Zhang LS, Hu XY, Yao LY, et al. Prophylactic effects of duloxetine on post-stroke depression symptoms:an open single-blind trial. Eur Neurol. 2013;69:336–343.
70. Davis R, Wilde MI. Mirtazapine:a review of its pharmacology and therapeutic potential in the management of major depression. CNS Drugs. 1996;5:389–402.
71. Niedermaier N, Bohrer E, Schulte K, et al. Prevention and treatment of poststroke depression with mirtazapine in patients with acute stroke. J Clin Psychiatry. 2004;65:1619–1623.
72. Rampello L, Chiechio S, Nicoletti G, et al. Prediction of the response to citalopram and reboxetine in post-stroke depressed patients. Psychopharmacology (Berl). 2004;173:73–78.• Interesting manuscript that suggests the possibility of differentiating the treatments according to the symptomatology.
73. Pardini M, Cordano C, Benassi F, et al. Agomelatine but not melatonin improves fatigue perception:a longitudinal proof-of-concept study. Eur Neuropsychopharmacol. 2014;24:939–944.
74. Thome J, Foley P. Agomelatine:an agent against anhedonia and abulia? J Neural Transm (Vienna). 2015;122(Suppl 1):S3–S7.
75. Robinson RG, Jorge RE, Clarence-Smith K. Double-blind randomized treatment of poststroke depression using nefiracetam. J Neuropsychiatry Clin Neurosci. 2008;20:178–184.
76. Starkstein SE, Brockman S, Hatch KK, et al. A randomized, placebo-controlled, double-blind efficacy study of nefiracetam to treat poststroke apathy. J Stroke Cerebrovasc Dis. 2016;25:1119–1127.
77. Hu Y, Xing H, Dong X, et al. Pioglitazone is an effective treatment for patients with post-stroke depression combined with type 2 diabetes mellitus. Exp Ther Med. 2015;10:1109–1114.
78. Lazarus LW, Winemiller DR, Lingam VR, et al. Efficacy and side effects of methylphenidate for poststroke depression. J Clin Psychiatry. 1992;53:447–449.
79. Berkowitz HL. Modafinil in poststroke depression. Psychosomatics. 2005;46:93–94.
80. Stahl SM. Mechanism of action of the SPARI vilazodone:serotonin 1A partial agonist and reuptake inhibitor. CNS Spectr. 2014;19:105–109.
81. McCormack PL. Vilazodone:a review in major depressive disorder in adults. Drugs. 2015;75:1915–1923.
82. Mago R, Tripathi N, Andrade C. Cardiovascular adverse effects of newer antidepressants. Expert Rev Neurother. 2014;14:539–551.
83. Citrome L. Levomilnacipran for major depressive disorder:a systematic review of the efficacy and safety profile for this newly approved antidepressant–what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2013;67:1089–1104.
84. Palmer EC, Binns LN, Carey H. Levomilnacipran:a new serotonin-norepinephrine reuptake inhibitor for the treatment of major depressive disorder. Ann Pharmacother. 2014;48:1030–1039.
85. Thase ME, Gommoll C, Chen C, et al. Effects of levomilnacipran extended-release on motivation/energy and functioning in adults with major depressive disorder. Int Clin Psychopharmacol. 2016;31:332–340.
86. Deardorff WJ, Grossberg, Gt. A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine. Expert Opin Pharmacother. 2014;15:2525–2542.
87. Connolly KR, Thase ME. Vortioxetine:a new treatment for major depressive disorder. Expert Opin Pharmacother. 2016;17:421–431.
88. McIntyre RS, Harrison J, Loft H, et al.The effects of vortioxetine on cognitive function in patients with major depressive disorder:a meta-analysis of three randomized controlled trials. Int J Neuropsychopharmacol. 2016. Epub ahead of print.
89. Harrison JE, Lophaven S, Olsen CK. Which cognitive domains are improved by treatment with vortioxetine? Int J Neuropsychopharmacol. 2016;19:pyw054. Available from:https://academic.oup.com/ijnp/article-lookup/doi/10.1093/ijnp/pyw054
90. Chen G, Zhang W, Serenko M. Lack of effect of multiple doses of vortioxetine on the pharmacokinetics and pharmacodynamics of aspirin and warfarin. J Clin Pharmacol. 2015;55:671–679.
91. Carta MG, Pala AN, Finco G, et al. Depression and cerebrovascular disease:could vortioxetine represent a valid treatment option? Clin Pract Epidemiol Ment Health. 2015;11:144–149.
92. Turner-Stokes L, Hassan N. Depression after stroke:a review of the evidence base to inform the development of an integrated care pathway. Part 2:Treatment alternatives. Clin Rehabil. 2002;16:248–260.
93. SPREAD - Stroke Prevention and Educational Awareness Diffusion:ictus cerebrale:linee guida italiane di prevenzione e trattamento. http://www iso-spread it/.
94. Paolucci S, Gandolfo C, Provinciali L, et al. Quantification of the risk of post stroke depression:the Italian multicenter observational study DESTRO. Acta Psychiatr Scand. 2005;112:272–278.
95. Hackett ML, Anderson CS. Frequency, management, and predictors of abnormal mood after stroke:the Auckland Regional Community Stroke (ARCOS) study, 2002 to 2003. Stroke. 2006;37:2123–2128.
96. Chen Y, Patel NC, Guo JJ, et al. Antidepressant prophylaxis for poststroke depression:a meta-analysis. Int Clin Psychopharmacol. 2007;22:159–166.
97. Mead GE, Hsieh CF, Lee R, et al. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev. 2012;11:CD009286.•• An important review on possible favorable action of antidepressants on stroke recovery.
98. Siepmann T, Penzlin AI, Kepplinger J, et al. Selective serotonin reuptake inhibitors to improve outcome in acute ischemic stroke:possible mechanisms and clinical evidence. Brain Behav. 2015;5:e00373.
99. Kraglund KL, Mortensen JK, Grove EL, et al. TALOS:a multicenter, randomized, double-blind, placebo-controlled trial to test the effects of citalopram in patients with acute stroke. Int J Stroke. 2015;10:985–987.